Moderna to Present Flu and RSV Vaccine Data at ESCMID 2026 Global Congress

Key Facts

1Moderna will present revaccination data for its investigational influenza vaccine mRNA-1010 and its RSV vaccine mRESVIA.

2The data will be presented at the ESCMID Global Congress in Munich in April 2026.

3The analysis focuses on safety and immunogenicity in adults aged 50 and older.

Moderna, Inc. has announced it will present late-breaking oral presentations regarding its seasonal influenza and RSV vaccines at the ESCMID Global Congress in April 2026. The presentations will feature revaccination data for the investigational mRNA-1010 influenza vaccine and the mRESVIA vaccine for RSV. The analysis specifically focuses on the safety and immunogenicity profiles in adults aged 50 and older. Moderna aims to share exploratory findings on the effectiveness of sequential mRNA vaccine administration compared to traditional egg-based alternatives. This move highlights the company's ongoing efforts to diversify its product pipeline beyond its COVID-19 offerings. Clinical data presentations of this nature are considered key catalysts for biotech stocks like MRNA, signaling long-term growth potential.